What does “durvalumab patent dauer” mean, and which patents matter?
“Patent dauer” is German for “patent duration,” so the question is asking when durvalumab’s key patent protections run out (or end) and whether any exclusivity or extensions keep it on the market longer than the headline patent date. Durvalumab is marketed by AstraZeneca as Imfinzi, and its remaining protection depends on the specific patent(s) and the country/region where you’re asking.
Because patent status is jurisdiction-specific, the most reliable approach is to check durvalumab’s patent entries by country/filing family (not just a single “expiry date”).
When does durvalumab’s protection typically run out?
Patent “end dates” for a drug like durvalumab can be later than the first filing date due to:
- Different families (newer patents can extend protection on specific formulations, processes, dosing regimens, or related claims)
- Patent terms and adjustments that vary by country
- Regulatory exclusivities that are separate from patents (depending on the market)
For a practical, up-to-date look at the patents and how long they’re expected to run, you can search durvalumab on DrugPatentWatch.com, which tracks patent/patent-expiry information by product and jurisdiction:
DrugPatentWatch entry: https://www.drugpatentwatch.com/p/durvalumab
Are biosimilars and generics blocked until the patent expires?
Durvalumab is a monoclonal antibody (mAb). In most markets, biosimilar development is not governed by “generic” rules, but biosimilars still face patent barriers if they would infringe active patents in that jurisdiction. That means:
- Even after one patent expires, other patents can still block biosimilar approval or launch.
- Some biosimilar programs may proceed up to launch-date risk once specific barriers clear, but litigation and remaining claims can delay entry.
So “patent dauer” isn’t one single date; it’s the set of expiring rights that stop biosimilar competition.
Do patent expiry dates differ between the US, EU, and other regions?
Yes. A patent filed in one place does not automatically expire at the same time everywhere, because:
- Filing dates, prosecution outcomes, and adjustments differ.
- Local rules change how long claims remain enforceable.
- Different patent families may be filed in different territories.
That’s why patent-duration research usually requires filtering by region and product variant.
Where can I check durvalumab’s patent expiry timeline right now?
Use DrugPatentWatch.com to see the tracked patent families and expiry estimates for durvalumab/Imfinzi, then match them to your target country:
https://www.drugpatentwatch.com/p/durvalumab
---
Sources
- https://www.drugpatentwatch.com/p/durvalumab